|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
|
EP1621206A1
(en)
|
1994-12-12 |
2006-02-01 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric cytokines and uses thereof
|
|
WO1997003193A1
(en)
|
1995-07-11 |
1997-01-30 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
DE69735421T2
(de)
|
1996-04-24 |
2006-10-19 |
The Regents Of The University Of Michigan, Ann Arbor |
Gegen inaktivierung resistenter faktor viii
|
|
MXPA00010241A
(es)
|
1998-04-27 |
2004-09-06 |
Opperbas Holding Bv |
Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
JP2005518181A
(ja)
|
2001-01-12 |
2005-06-23 |
ジ・アメリカン・ナショナル・レッド・クロス |
第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
|
|
EP2110385A1
(en)
|
2001-06-14 |
2009-10-21 |
The Scripps Research Institute |
Stabilized factor VIII with engineered disulfide bonds
|
|
WO2003076567A2
(en)
|
2002-03-05 |
2003-09-18 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
|
CA2484155C
(en)
|
2002-04-29 |
2015-10-13 |
Baxter International Inc. |
Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
AU2004215912B2
(en)
|
2003-02-26 |
2009-03-26 |
Nektar Therapeutics |
Polymer-factor VIII moiety conjugates
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
DE602004031390D1
(de)
|
2003-05-06 |
2011-03-24 |
Syntonix Pharmaceuticals Inc |
Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
|
|
CA2528591C
(en)
|
2003-06-12 |
2013-01-08 |
Eli Lilly And Company |
Glp-1 analog fusion proteins
|
|
KR20060124656A
(ko)
|
2003-12-31 |
2006-12-05 |
메르크 파텐트 게엠베하 |
개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
SI1824988T1
(sl)
|
2004-11-12 |
2017-11-30 |
Bayer Healthcare Llc |
Usmerjena modifikacija FVIII
|
|
KR20070092754A
(ko)
|
2004-12-27 |
2007-09-13 |
백스터 인터내셔널 인코포레이티드 |
중합체 - 폰 빌레브란트 인자 - 접합체
|
|
AU2006233638A1
(en)
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation Factor VIII with enhanced stability and its derivates
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
NZ572050A
(en)
|
2006-03-31 |
2011-09-30 |
Baxter Int |
Factor VIII conjugated to polyethylene glycol
|
|
EP2032607B2
(en)
|
2006-06-14 |
2017-02-22 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
EP3231440A1
(en)
|
2006-12-22 |
2017-10-18 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
|
CN103739712B
(zh)
|
2008-06-24 |
2016-10-05 |
德国杰特贝林生物制品有限公司 |
具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
|
|
MX2012005527A
(es)
|
2009-11-13 |
2012-08-08 |
Grifols Therapeutics Inc |
Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
EA035323B1
(ru)
|
2012-01-12 |
2020-05-28 |
Биовератив Терапьютикс Инк. |
Полипептиды химерного фактора viii и их применение
|
|
ES2651523T3
(es)
|
2012-02-15 |
2018-01-26 |
Csl Behring Gmbh |
Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
|
|
US20150080309A1
(en)
|
2012-04-24 |
2015-03-19 |
Nova Nordisk A/S |
Compounds Suitable for Treatment of Haemophilia
|
|
US10138291B2
(en)
|
2012-07-11 |
2018-11-27 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
DK2796145T3
(da)
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
|
EP3008084A2
(en)
|
2013-06-12 |
2016-04-20 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
|
WO2014210558A1
(en)
*
|
2013-06-28 |
2014-12-31 |
Biogen Idec Ma Inc. |
Thrombin cleavable linker with xten and its uses thereof
|
|
AU2015283822B2
(en)
*
|
2014-07-02 |
2019-10-03 |
CSL Behring Lengnau AG |
Modified von willebrand factor
|
|
SG11201708755WA
(en)
*
|
2015-05-22 |
2017-12-28 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
CN107810194B
(zh)
*
|
2015-05-22 |
2021-10-08 |
康诺贝林伦瑙有限公司 |
用于制备经修饰的血管性血友病因子的方法
|
|
SG10201912857XA
(en)
*
|
2016-01-07 |
2020-02-27 |
CSL Behring Lengnau AG |
Mutated von willebrand factor
|
|
SG11201805497QA
(en)
*
|
2016-01-07 |
2018-07-30 |
Csl Behring Recombinant Facility Ag |
Mutated truncated von willebrand factor
|